Breakfast Symposium: Novel Therapeutic Approaches to IBD: Considerations for Optimal Positioning in Clinical Practice

Breakfast Symposium: Novel Therapeutic Approaches to IBD: Considerations for Optimal Positioning in Clinical Practice

National Meeting
Program Details

Registration for the symposium is now available. 

A Friday Satellite Symposium: Advances in Inflammatory Bowel Diseases Congress 2019

Walt Disney World Swan and Dolphin Resort
Meeting Room:  Northern Hemisphere A

Orlando, Florida

December 13, 2019

6:00 AM - 6:30 AM, Registration and Complimentary Lunch Buffet
6:30 AM - 7:30 AM, Interactive Symposium and Q&A Session



David T. Rubin, MD, FACG
University of Chicago Medicine
Chicago, Illinois


Christina Y. Ha, MD
Cedars Sinai Medical Center
Los Angeles, California

Bruce E. Sands, MD, MS
Icahn School of Medicine at Mount Sinai
New York, New York

Intended Learners

Designed and certified for the entire IBD healthcare team and includes education for gastroenterologists, pediatric gastroenterologists, surgeons, physicians, PhDs, researchers, pharmacists, nurse practitioners, physician assistants, gastroenterology nurses, and residents/fellows/students.

Learning Objectives

After participating in this activity, learners should be able to:

  • Describe the current understanding of IBD pathophysiology with respect to inflammatory signaling pathways and potential therapeutic targets
  • Evaluate the mechanisms of action and available efficacy and safety data surrounding new and emerging therapies for the treatment of IBD
  • Integrate the latest clinical data into current and future personalized therapeutic strategies for the management of IBD
Activity Overview

Participants will obtain a pre- and post-activity survey, evaluation, and activity materials onsite. Attendees will be asked to complete the pre-activity survey before the lecture and the post-activity survey and evaluation immediately after the lecture. A faculty question-and-answer session will follow the presentation.

Instructions for Receiving Documentation of Credit

Participants are requested to complete the electronic evaluation immediately following the educational session or complete the online evaluation within 2 weeks of the event. Participants who submit an electronic evaluation onsite will receive documentation of credit via email within 8 weeks. Individuals who participate in the activity and submit the evaluation form online at will immediately receive documentation of credit.  Participants will be asked to log in or create an account at


 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME), Imedex, and the University of Cincinnati (UC). NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 


 The University of Cincinnati (UC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

University of Cincinnati designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.


This continuing nursing education activity awards 1.00 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hour. 


This live, knowledge-based activity (Universal Activity Number JA0006201-9999-19-182-L01-P) has been approved for a maximum of 1 contact hour (0.01 CEU).  

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is January 12, 2020 (60 DAYS AFTER ACTIVITY.) Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation 

ADA Statement

Imedex, an HMP Company complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137. 

Planning Committee

The planning committee comprises of David T. Rubin, Md, FACG; Chistina Y. Ha, MD; and Bruce E. Sands, MD, MS

Imedex planners and staff include Chris Bolwell and Kelly Jackson.

NACCME planners and staff include Mike Kearney, Mary Johnson, and Jennifer Ilcyn.

University of Cincinnati (UC) planners and staff include Barbara Forney, Bruce Gebhardt, MD, and Susan Tyler.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty is reported the following:

David T. Rubin, MD, FACG reports being a Consultant for Abbvie Abgenomics Allergan, Inc. Biomica Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone Seres Therapeutics, Shire, Takeda, and Target PharmaSolutions, Inc.; Grant/Research Support for Abbvie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire and Takeda; as well as being American College of Gastroenterology - Board of Trustees Cornerstones Health, Inc. (non-profit), Co-Founder GoDuRn, LLC, Co-Founder (no financial support recvd)

Christina Y. Ha, MD reports being a Consultant/Advisory Board Member for AbbVie, Genetech, Janssen, Pfizer, Samsung Bioepis and Takeda; offering Grant support for Pfizer; and being on the Speakers Bureau for AbbVie and Medical Speakers Network

Bruce E. Sands, MD, MS reports being a Consultant for Ingelheim, Boston Pharmaceuticals, Capella Bioscience,Celltrion Healthcare, Genentech, Hoffmann-La Roche, AG Ironwood Pharmaceuticals, Janssen, Lilly, Morphic Therapeutic, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Laboratorie, Salix, Shire, Takeda Pharmaceuticals, TARGET PharmaSolutions, Theravance Biopharma, and Vivelix Pharmaceuticals; and offering Grant/Research Support for Theravance Biopharma

Chris Bolwell  is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to

Grant Support

This activity has been supported through an independent educational grant from Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Privacy Policy

Imedex protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Imedex and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.